Aiming to accelerate the development of Copiktra (duvelisib) for treatment of peripheral T-cell lymphoma (PTCL) — an aggressive type of non-Hodgkin’s lymphoma — Verastem has announced a collaboration with the Leukemia & Lymphoma Society (LLS). An open-label Phase 1 trial (NCT01476657), including 16 patients who had failed prior treatment regimens, showed an overall response rate of 50%, including three (19%) complete responses. Now, Verastem is conducting a larger trial to confirm the findings. The follow-up Phase 2 trial is called PRIMO (NCT03372057).

https://lymphomanewstoday.com/2018/11/14/verastem-advances-copiktra-for-peripheral-t-cell-lymphoma-under-lls-therapy-acceleration-program/